axitinib sustained release bioerodible implant (AR-14034 SR) / Alcon - LARVOL DELTA

NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=139 | Active, not recruiting | Sponsor: Alcon Research | Trial primary completion date: Oct 2027 ➔ May 2027

Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=139 | Active, not recruiting | Sponsor: Alcon Research | Recruiting ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=140 | Recruiting | Sponsor: Alcon Research | Trial completion date: Apr 2027 ➔ Sep 2027 | Trial primary completion date: Apr 2027 ➔ Sep 2027

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=140 | Recruiting | Sponsor: Aerie Pharmaceuticals | Trial completion date: Oct 2025 ➔ Feb 2027 | Trial primary completion date: Oct 2025 ➔ Feb 2027

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=140 | Recruiting | Sponsor: Aerie Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=140 | Not yet recruiting | Sponsor: Aerie Pharmaceuticals | Trial completion date: Oct 2026 ➔ Jan 2027 | Trial primary completion date: Oct 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=140 | Not yet recruiting | Sponsor: Aerie Pharmaceuticals | Initiation date: Aug 2023 ➔ Nov 2023

Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

AR-14034 SR Implant Inhibits Retinal Vascular Leakage In A VEGF Challenge Model For Up To 12 Months (ARVO 2023) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NOVA-1: Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=140 | Not yet recruiting | Sponsor: Aerie Pharmaceuticals

New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration